首页 > 最新文献

Breast Cancer : Basic and Clinical Research最新文献

英文 中文
CT Texture Analysis in Breast Cancer Patients Undergoing CT-Guided Bone Biopsy: Correlations With Histopathology.
IF 1.8 Q3 ONCOLOGY Pub Date : 2025-01-29 eCollection Date: 2025-01-01 DOI: 10.1177/11782234241305886
Silvio Wermelskirchen, Jakob Leonhardi, Anne-Kathrin Höhn, Georg Osterhoff, Nikolas Schopow, Susanne Briest, Timm Denecke, Hans-Jonas Meyer

Background: Texture analysis has the potential to deliver quantitative imaging markers. Patients receiving computed tomography (CT)-guided percutaneous bone biopsies could be characterized using texture analysis derived from CT. Especially for breast cancer (BC) patients, it could be crucial to better predict the outcome of the biopsy to better reflect the immunohistochemistry status of the tumor.

Objectives: The present study examined the relationship between texture features and outcomes in patients with BC receiving CT-guided bone biopsies.

Design: This study is based on a retrospective analysis.

Methods: The present study included a total of 66 patients. All patients proceeded to undergo a CT-guided percutaneous bone biopsy, using an 11-gauge coaxial needle. Clinical and imaging characteristics as well as CT texture analysis were included in the analysis. Logistic regression analysis was performed to predict negative biopsy results.

Results: Overall, 33 patients had osteolytic metastases (50%) and 33 had osteoblastic metastases (50%). The overall positivity rate for the biopsy was 75%. The clinical model exhibited a predictive accuracy for a positive biopsy result, as indicated by an area under the curve (AUC) of 0.73 [95% confidence interval (CI) = 0.63-0.83]. Several CT texture features were different between Luminal A and Luminal B cancers; the best discrimination was reached for "WavEnHH_s-3" with a P-value of .002. When comparing triple-negative to non-triple-negative cancers, several CT texture features were different, the best discrimination achieved "S(5,5)SumVarnc" with a P-value of .01. For the Her 2 discrimination, only 3 parameters reached statistical significance, "S(4,-4)SumOfSqs" with a P-value of .01.

Conclusions: The utilization of CT texture features may facilitate a more accurate characterization of bone metastases in patients with BC. There is the potential to predict the immunohistochemical subtype with a high degree of accuracy. The identified parameters may prove useful in clinical decision-making and could help to identify patients at risk of a negative biopsy result.

{"title":"CT Texture Analysis in Breast Cancer Patients Undergoing CT-Guided Bone Biopsy: Correlations With Histopathology.","authors":"Silvio Wermelskirchen, Jakob Leonhardi, Anne-Kathrin Höhn, Georg Osterhoff, Nikolas Schopow, Susanne Briest, Timm Denecke, Hans-Jonas Meyer","doi":"10.1177/11782234241305886","DOIUrl":"https://doi.org/10.1177/11782234241305886","url":null,"abstract":"<p><strong>Background: </strong>Texture analysis has the potential to deliver quantitative imaging markers. Patients receiving computed tomography (CT)-guided percutaneous bone biopsies could be characterized using texture analysis derived from CT. Especially for breast cancer (BC) patients, it could be crucial to better predict the outcome of the biopsy to better reflect the immunohistochemistry status of the tumor.</p><p><strong>Objectives: </strong>The present study examined the relationship between texture features and outcomes in patients with BC receiving CT-guided bone biopsies.</p><p><strong>Design: </strong>This study is based on a retrospective analysis.</p><p><strong>Methods: </strong>The present study included a total of 66 patients. All patients proceeded to undergo a CT-guided percutaneous bone biopsy, using an 11-gauge coaxial needle. Clinical and imaging characteristics as well as CT texture analysis were included in the analysis. Logistic regression analysis was performed to predict negative biopsy results.</p><p><strong>Results: </strong>Overall, 33 patients had osteolytic metastases (50%) and 33 had osteoblastic metastases (50%). The overall positivity rate for the biopsy was 75%. The clinical model exhibited a predictive accuracy for a positive biopsy result, as indicated by an area under the curve (AUC) of 0.73 [95% confidence interval (CI) = 0.63-0.83]. Several CT texture features were different between Luminal A and Luminal B cancers; the best discrimination was reached for \"WavEnHH_s-3\" with a <i>P</i>-value of .002. When comparing triple-negative to non-triple-negative cancers, several CT texture features were different, the best discrimination achieved \"S(5,5)SumVarnc\" with a <i>P</i>-value of .01. For the Her 2 discrimination, only 3 parameters reached statistical significance, \"S(4,-4)SumOfSqs\" with a <i>P</i>-value of .01.</p><p><strong>Conclusions: </strong>The utilization of CT texture features may facilitate a more accurate characterization of bone metastases in patients with BC. There is the potential to predict the immunohistochemical subtype with a high degree of accuracy. The identified parameters may prove useful in clinical decision-making and could help to identify patients at risk of a negative biopsy result.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234241305886"},"PeriodicalIF":1.8,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Absence of Cysteine and Iron Chelation Induces Ferroptosis in Triple-Negative Breast Cancer Cells. 缺半胱氨酸和铁螯合诱导三阴性乳腺癌细胞铁下垂。
IF 1.8 Q3 ONCOLOGY Pub Date : 2025-01-16 eCollection Date: 2025-01-01 DOI: 10.1177/11782234241311012
Manvi Agarwal Neeraj, JunJeong Choi

Background: Ferroptosis is a recently studied form of programmed cell death characterized by lipid peroxides accumulation in the cells. This process occurs when a cell's antioxidant capacity is disturbed resulting in the inability of the cell to detoxify the toxic peroxides. Two major components that regulate ferroptosis are cysteine and iron.

Objective: This study aimed to determine the effect of cysteine deficiency and iron chelation on triple-negative breast cancer (TNBC) ferroptosis in a lipid-enriched microenvironment.

Design: The study has a laboratory-based experimental design. This study used the MDA-MB-231 cell line in various in vitro cell culture systems to investigate the research question.

Methods: For the first part of the study, we subjected MDA-MB-231 cells to grow in cysteine-absent adipocyte-conditioned media. In the second half, we treated MDA-MB-231 cells with iron chelator, deferoxamine. BODIPY imaging and western blot were carried out to observe ferroptosis in the cells under the 2 conditions.

Results: The results showed that cysteine absence in the conditioned media was able to reduce the formation of lipid droplets, which increased the greater access to free fatty acids to undergo oxidation, therefore inducing ferroptosis. On the contrary, cells when treated with deferoxamine along with erastin (ferroptosis-inducing drug), showed an increase in cell iron content was observed, later inducing ferroptosis.

Conclusion: Our results show an alternative function of cysteine and deferoxamine, one regulating lipid droplets and the other inducing ferroptosis, although an inhibitor of the same, respectively.

背景:铁死亡是最近研究的一种程序性细胞死亡形式,其特征是细胞中脂质过氧化物的积累。当细胞的抗氧化能力受到干扰,导致细胞无法解毒有毒的过氧化物时,就会发生这种过程。调节铁下垂的两种主要成分是半胱氨酸和铁。目的:本研究旨在确定半胱氨酸缺乏和铁螯合对富脂微环境下三阴性乳腺癌(TNBC)铁下垂的影响。设计:本研究采用实验室为基础的实验设计。本研究利用MDA-MB-231细胞系在多种体外细胞培养体系中进行研究。方法:在研究的第一部分,我们将MDA-MB-231细胞置于无半胱氨酸脂肪细胞条件培养基中生长。后半部分用铁螯合剂去铁胺处理MDA-MB-231细胞。采用BODIPY显像和western blot观察两种条件下细胞的铁下垂情况。结果:结果表明,条件培养基中半胱氨酸的缺失能够减少脂滴的形成,从而增加游离脂肪酸进行氧化的机会,从而诱导铁下垂。相反,当细胞与去铁胺和erastin(诱导铁死亡的药物)一起处理时,观察到细胞铁含量增加,随后诱导铁死亡。结论:半胱氨酸和去铁胺具有调节脂滴和诱导铁下垂的作用,尽管它们是相同的抑制剂。
{"title":"Absence of Cysteine and Iron Chelation Induces Ferroptosis in Triple-Negative Breast Cancer Cells.","authors":"Manvi Agarwal Neeraj, JunJeong Choi","doi":"10.1177/11782234241311012","DOIUrl":"10.1177/11782234241311012","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is a recently studied form of programmed cell death characterized by lipid peroxides accumulation in the cells. This process occurs when a cell's antioxidant capacity is disturbed resulting in the inability of the cell to detoxify the toxic peroxides. Two major components that regulate ferroptosis are cysteine and iron.</p><p><strong>Objective: </strong>This study aimed to determine the effect of cysteine deficiency and iron chelation on triple-negative breast cancer (TNBC) ferroptosis in a lipid-enriched microenvironment.</p><p><strong>Design: </strong>The study has a laboratory-based experimental design. This study used the MDA-MB-231 cell line in various in vitro cell culture systems to investigate the research question.</p><p><strong>Methods: </strong>For the first part of the study, we subjected MDA-MB-231 cells to grow in cysteine-absent adipocyte-conditioned media. In the second half, we treated MDA-MB-231 cells with iron chelator, deferoxamine. BODIPY imaging and western blot were carried out to observe ferroptosis in the cells under the 2 conditions.</p><p><strong>Results: </strong>The results showed that cysteine absence in the conditioned media was able to reduce the formation of lipid droplets, which increased the greater access to free fatty acids to undergo oxidation, therefore inducing ferroptosis. On the contrary, cells when treated with deferoxamine along with erastin (ferroptosis-inducing drug), showed an increase in cell iron content was observed, later inducing ferroptosis.</p><p><strong>Conclusion: </strong>Our results show an alternative function of cysteine and deferoxamine, one regulating lipid droplets and the other inducing ferroptosis, although an inhibitor of the same, respectively.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234241311012"},"PeriodicalIF":1.8,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare Cell Population Analysis in Early-Stage Breast Cancer Patients. 早期乳腺癌患者的罕见细胞群分析。
IF 1.8 Q3 ONCOLOGY Pub Date : 2025-01-10 eCollection Date: 2025-01-01 DOI: 10.1177/11782234241310596
Stefan Schreier, Prapaphan Budchart, Suparerk Borwornpinyo, Lakkana Adireklarpwong, Prakasit Chirappapha, Wannapong Triampo, Panuwat Lertsithichai

Background: Circulating rare cells participate in breast cancer evolution as systemic components of the disease and thus, are a source of theranostic information. Exploration of cancer-associated rare cells is in its infancy.

Objectives: We aimed to investigate and classify abnormalities in the circulating rare cell population among early-stage breast cancer patients using fluorescence marker identification and cytomorphology. In addition, we sought to determine the dependency of these markers on the presence of tumors.

Design: We evaluated the validity of a multi-rare-cell detection platform and demonstrated the utility of a specific rare cell subset as a novel approach to characterize the breast cancer system. Sampling was conducted both before and after tumor resection.

Methods: Linearity of the Rarmax platform was established using a spike-in approach. The platform includes red blood cell lysis, leukocyte depletion and high-resolution fluorescence image recording. Rare cell analysis was conducted on 28 samples (before and after surgery) from 14 patients with breast cancer, 20 healthy volunteers and 9 noncancer control volunteers. In-depth identification of rare cells, including circulating tumor cells, endothelial-like cells, erythroblasts, and inflammation-associated cells, was performed using a phenotype and morphology-based classification system.

Results: The platform performed linearly over a range of 5 to 950 spiked cells, with an average recovery of 84.6%. Circulating epithelial and endothelial-like cell subsets have been demonstrated to be associated with or independent of cancer with tumor presence. Furthermore, certain cell profile patterns may be associated with treatment-related adverse effects. The sensitivity in detecting tumor-presence and cancer-associated abnormality before surgery was 43% and 85.7%, respectively, and the specificity was 100% and 96.6%, respectively.

Conclusion: This study supports the idea of a cancer-associated rare cell abnormality to represent tumor entities as well as systemic cancer. The latter is independent of the apparent clinical cancer.

背景:循环的稀有细胞作为疾病的系统性组成部分参与乳腺癌的演变,因此是治疗信息的来源。对癌症相关的稀有细胞的探索还处于起步阶段。目的:我们旨在利用荧光标记识别和细胞形态学来研究和分类早期乳腺癌患者循环罕见细胞群的异常。此外,我们试图确定这些标志物对肿瘤存在的依赖性。设计:我们评估了多罕见细胞检测平台的有效性,并证明了特定罕见细胞亚群作为表征乳腺癌系统的新方法的实用性。肿瘤切除前后均进行采样。方法:采用尖峰法建立Rarmax平台的线性关系。该平台包括红细胞裂解、白细胞消耗和高分辨率荧光图像记录。对14名乳腺癌患者、20名健康志愿者和9名非癌症对照志愿者的28个样本(手术前后)进行了罕见细胞分析。利用基于表型和形态的分类系统,对包括循环肿瘤细胞、内皮样细胞、红细胞和炎症相关细胞在内的稀有细胞进行了深入鉴定。结果:该平台在5 ~ 950个加标细胞范围内呈线性,平均加标回收率为84.6%。循环上皮细胞和内皮样细胞亚群已被证明与肿瘤存在的癌症相关或独立。此外,某些细胞谱模式可能与治疗相关的不良反应有关。术前检测肿瘤存在及肿瘤相关异常的敏感性分别为43%和85.7%,特异性分别为100%和96.6%。结论:本研究支持癌症相关的罕见细胞异常代表肿瘤实体和全身性癌症的观点。后者与明显的临床肿瘤无关。
{"title":"Rare Cell Population Analysis in Early-Stage Breast Cancer Patients.","authors":"Stefan Schreier, Prapaphan Budchart, Suparerk Borwornpinyo, Lakkana Adireklarpwong, Prakasit Chirappapha, Wannapong Triampo, Panuwat Lertsithichai","doi":"10.1177/11782234241310596","DOIUrl":"10.1177/11782234241310596","url":null,"abstract":"<p><strong>Background: </strong>Circulating rare cells participate in breast cancer evolution as systemic components of the disease and thus, are a source of theranostic information. Exploration of cancer-associated rare cells is in its infancy.</p><p><strong>Objectives: </strong>We aimed to investigate and classify abnormalities in the circulating rare cell population among early-stage breast cancer patients using fluorescence marker identification and cytomorphology. In addition, we sought to determine the dependency of these markers on the presence of tumors.</p><p><strong>Design: </strong>We evaluated the validity of a multi-rare-cell detection platform and demonstrated the utility of a specific rare cell subset as a novel approach to characterize the breast cancer system. Sampling was conducted both before and after tumor resection.</p><p><strong>Methods: </strong>Linearity of the Rarmax platform was established using a spike-in approach. The platform includes red blood cell lysis, leukocyte depletion and high-resolution fluorescence image recording. Rare cell analysis was conducted on 28 samples (before and after surgery) from 14 patients with breast cancer, 20 healthy volunteers and 9 noncancer control volunteers. In-depth identification of rare cells, including circulating tumor cells, endothelial-like cells, erythroblasts, and inflammation-associated cells, was performed using a phenotype and morphology-based classification system.</p><p><strong>Results: </strong>The platform performed linearly over a range of 5 to 950 spiked cells, with an average recovery of 84.6%. Circulating epithelial and endothelial-like cell subsets have been demonstrated to be associated with or independent of cancer with tumor presence. Furthermore, certain cell profile patterns may be associated with treatment-related adverse effects. The sensitivity in detecting tumor-presence and cancer-associated abnormality before surgery was 43% and 85.7%, respectively, and the specificity was 100% and 96.6%, respectively.</p><p><strong>Conclusion: </strong>This study supports the idea of a cancer-associated rare cell abnormality to represent tumor entities as well as systemic cancer. The latter is independent of the apparent clinical cancer.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234241310596"},"PeriodicalIF":1.8,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occult Breast Cancer in High-Risk Gene-Positive Pakistani Women Undergoing Contralateral Prophylactic Mastectomy/Prophylactic Mastectomy: Implications for Sentinel Lymph Node Biopsy. 高危基因阳性巴基斯坦妇女行对侧预防性乳房切除术/预防性乳房切除术的隐匿性乳腺癌:前哨淋巴结活检的意义
IF 1.8 Q3 ONCOLOGY Pub Date : 2025-01-02 eCollection Date: 2025-01-01 DOI: 10.1177/11782234241311018
Mehwish Mooghal, Wajiha Khan, Saba Anjum, Hafsa Shaikh, Safna Naozer Virji, Lubna M Vohra

Introduction: Sentinel lymph node biopsy (SLNB) of the axilla is standard in breast cancer (BC) management; however, its role in prophylactic/contralateral prophylactic mastectomy (CPM) is still questioned. To avoid future consequences on surgical morbidity and socioeconomic aspects in low and middle-income countries (LMICs), we intend to determine the prevalence of occult breast cancer (OBC) among CPM cases.

Objective: To determine the prevalence of OBC in patients undergoing prophylactic mastectomy (PM).

Design: This is a retrospective cohort study.

Materials and methods: This retrospective cohort study is conducted at a tertiary-care hospital from January 2017 to December 2022. All individuals with the positive genetic test for high-risk breast cancer (HRBC) genes who underwent PMs/CPM at our centre were included. We analysed data using SPSS version 23.0.

Results: Twenty-six mutation-positive females underwent PM/CPM (16.1%). Two (7.69%) of 26 had later post-PM recurrence. Only 8 (30.76%) patients had SLNB and all were negative. No OBC was seen in PM/CPM specimens, whereas 3 (11.5%) had atypical ductal hyperplasia (ADH). Two of the ADH had BI-RADS-1, whereas 1 was BI-RADS-4 (33.3%) on the preoperative assessment. Results also showed that with an increase in the tumour grade of the diseased breast, the BI-RADS score of the asymptomatic breast was subsequently increased (P = .029).

Conclusion: Our study shows negative OBCs in PM/CPM cases with persistently negative SLNB results; however, ADH is identified in 11.5% of specimens. Our results suggest that SLNB can be safely omitted in patients undergoing CPM, but, preoperatively, patient and disease factors should be considered.

腋窝前哨淋巴结活检(SLNB)是乳腺癌(BC)治疗的标准;然而,其在预防性/对侧预防性乳房切除术(CPM)中的作用仍然存在疑问。为了避免未来对低收入和中等收入国家(LMICs)手术发病率和社会经济方面的影响,我们打算确定隐匿性乳腺癌(OBC)在CPM病例中的患病率。目的:了解行预防性乳房切除术(PM)患者乳腺癌的发生率。设计:这是一项回顾性队列研究。材料与方法:本回顾性队列研究于2017年1月至2022年12月在一家三级医院进行。所有高危乳腺癌(HRBC)基因检测阳性的患者均在本中心接受了pm /CPM治疗。我们使用SPSS 23.0版本分析数据。结果:26例突变阳性女性接受了PM/CPM(16.1%)。26例中有2例(7.69%)pm后复发。仅有8例(30.76%)患者有SLNB,且均为阴性。PM/CPM标本中未见OBC,而3例(11.5%)有不典型导管增生(ADH)。2例ADH患者术前评估BI-RADS-1, 1例为BI-RADS-4(33.3%)。结果还显示,随着病变乳腺肿瘤分级的增加,无症状乳腺的BI-RADS评分随之增加(P = 0.029)。结论:我们的研究显示PM/CPM患者持续SLNB阴性的OBCs为阴性;然而,在11.5%的标本中发现ADH。我们的研究结果表明,在CPM患者中可以安全地省略SLNB,但术前应考虑患者和疾病因素。
{"title":"Occult Breast Cancer in High-Risk Gene-Positive Pakistani Women Undergoing Contralateral Prophylactic Mastectomy/Prophylactic Mastectomy: Implications for Sentinel Lymph Node Biopsy.","authors":"Mehwish Mooghal, Wajiha Khan, Saba Anjum, Hafsa Shaikh, Safna Naozer Virji, Lubna M Vohra","doi":"10.1177/11782234241311018","DOIUrl":"https://doi.org/10.1177/11782234241311018","url":null,"abstract":"<p><strong>Introduction: </strong>Sentinel lymph node biopsy (SLNB) of the axilla is standard in breast cancer (BC) management; however, its role in prophylactic/contralateral prophylactic mastectomy (CPM) is still questioned. To avoid future consequences on surgical morbidity and socioeconomic aspects in low and middle-income countries (LMICs), we intend to determine the prevalence of occult breast cancer (OBC) among CPM cases.</p><p><strong>Objective: </strong>To determine the prevalence of OBC in patients undergoing prophylactic mastectomy (PM).</p><p><strong>Design: </strong>This is a retrospective cohort study.</p><p><strong>Materials and methods: </strong>This retrospective cohort study is conducted at a tertiary-care hospital from January 2017 to December 2022. All individuals with the positive genetic test for high-risk breast cancer (HRBC) genes who underwent PMs/CPM at our centre were included. We analysed data using SPSS version 23.0.</p><p><strong>Results: </strong>Twenty-six mutation-positive females underwent PM/CPM (16.1%). Two (7.69%) of 26 had later post-PM recurrence. Only 8 (30.76%) patients had SLNB and all were negative. No OBC was seen in PM/CPM specimens, whereas 3 (11.5%) had atypical ductal hyperplasia (ADH). Two of the ADH had BI-RADS-1, whereas 1 was BI-RADS-4 (33.3%) on the preoperative assessment. Results also showed that with an increase in the tumour grade of the diseased breast, the BI-RADS score of the asymptomatic breast was subsequently increased (<i>P</i> = .029).</p><p><strong>Conclusion: </strong>Our study shows negative OBCs in PM/CPM cases with persistently negative SLNB results; however, ADH is identified in 11.5% of specimens. Our results suggest that SLNB can be safely omitted in patients undergoing CPM, but, preoperatively, patient and disease factors should be considered.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234241311018"},"PeriodicalIF":1.8,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab Induces Apoptosis and Cell Cycle Arrest in Triple-Negative Breast Cancer, Suggesting Repurposing Potential. 曲妥珠单抗在三阴性乳腺癌中诱导细胞凋亡和细胞周期阻滞,提示重新利用潜力。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-11-27 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241285411
Shaimaa Abdel-Ghany, Yasmin Khalid, Soha Mohamed, Gehan Mohamed, Engy Mohdy, Abeer Ezzat, Engy F Madian, Osama A Said, Mohamed A Abdel-Hakeem, Mahmoud Nazih, Ahmed Khoder, Hussein Sabit

Background: Breast cancer remains the most common invasive cancer in women worldwide. Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. Trastuzumab (Tz) is typically used to treat HER2-positive breast cancers, but its potential in TNBC is unclear.

Objectives: To investigate the effects of trastuzumab on cell viability, apoptosis, cell cycle progression, and gene expression in TNBC cell lines compared with HER2-positive and normal cell lines.

Design: This is an in vitro experimental pre-clinical study using cultured cancer cell lines.

Methods: MDA-MB-231 and 4T1 (TNBC), MCF-7 (HER2-positive), and HSF (normal) cell lines were treated with 20 μg/mL trastuzumab for 24 hours. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis by flow cytometry, cell cycle progression by DNA content analysis, and gene expression by qPCR.

Results: Trastuzumab significantly reduced cell viability and induced apoptosis in TNBC cell lines, comparable to effects in HER2-positive MCF-7 cells. Cell cycle analysis revealed G2/M phase arrest in TNBC cells. Gene expression analysis showed upregulation of ERBB2, NOTCH1, EGFR, PIK3CA, and PTEN in MDA-MB-231 cells, while 4T1 cells exhibited downregulation of most genes except NOTCH1.

Conclusion: This study provides initial evidence for trastuzumab's potential therapeutic effects in TNBC, despite low HER2 expression. The observed cytotoxicity, apoptosis induction, and cell cycle modulation in TNBC cells warrant further investigation into trastuzumab's mechanisms of action in HER2-negative contexts and its potential repurposing for TNBC treatment.

背景:乳腺癌仍然是全世界女性中最常见的浸润性癌症。三阴性乳腺癌(TNBC)是一种侵袭性亚型,治疗选择有限。曲妥珠单抗(Tz)通常用于治疗her2阳性乳腺癌,但其在TNBC中的潜力尚不清楚。目的:研究曲妥珠单抗与her2阳性和正常细胞系比较,对TNBC细胞系细胞活力、凋亡、细胞周期进展和基因表达的影响。设计:这是一项体外实验临床前研究,使用培养的癌细胞系。方法:用20 μg/mL曲妥珠单抗治疗MDA-MB-231和4T1 (TNBC)、MCF-7 (her2阳性)和HSF(正常)细胞系24小时。采用3-(4,5-二甲基噻唑-2-酰基)-2,5-二苯基溴化四唑(MTT)检测细胞活力,流式细胞术检测细胞凋亡,DNA含量分析细胞周期进展,qPCR检测基因表达。结果:曲妥珠单抗显著降低TNBC细胞系的细胞活力并诱导细胞凋亡,与her2阳性MCF-7细胞的作用相当。细胞周期分析显示TNBC细胞G2/M期阻滞。基因表达分析显示,MDA-MB-231细胞中ERBB2、NOTCH1、EGFR、PIK3CA和PTEN基因表达上调,而4T1细胞除NOTCH1外,其余基因表达下调。结论:该研究为曲妥珠单抗治疗TNBC的潜在疗效提供了初步证据,尽管HER2表达较低。在TNBC细胞中观察到的细胞毒性、细胞凋亡诱导和细胞周期调节值得进一步研究曲妥珠单抗在her2阴性情况下的作用机制及其在TNBC治疗中的潜在用途。
{"title":"Trastuzumab Induces Apoptosis and Cell Cycle Arrest in Triple-Negative Breast Cancer, Suggesting Repurposing Potential.","authors":"Shaimaa Abdel-Ghany, Yasmin Khalid, Soha Mohamed, Gehan Mohamed, Engy Mohdy, Abeer Ezzat, Engy F Madian, Osama A Said, Mohamed A Abdel-Hakeem, Mahmoud Nazih, Ahmed Khoder, Hussein Sabit","doi":"10.1177/11782234241285411","DOIUrl":"10.1177/11782234241285411","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains the most common invasive cancer in women worldwide. Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. Trastuzumab (Tz) is typically used to treat HER2-positive breast cancers, but its potential in TNBC is unclear.</p><p><strong>Objectives: </strong>To investigate the effects of trastuzumab on cell viability, apoptosis, cell cycle progression, and gene expression in TNBC cell lines compared with HER2-positive and normal cell lines.</p><p><strong>Design: </strong>This is an in vitro experimental pre-clinical study using cultured cancer cell lines.</p><p><strong>Methods: </strong>MDA-MB-231 and 4T1 (TNBC), MCF-7 (<i>HER2</i>-positive), and HSF (normal) cell lines were treated with 20 μg/mL trastuzumab for 24 hours. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis by flow cytometry, cell cycle progression by DNA content analysis, and gene expression by qPCR.</p><p><strong>Results: </strong>Trastuzumab significantly reduced cell viability and induced apoptosis in TNBC cell lines, comparable to effects in HER2-positive MCF-7 cells. Cell cycle analysis revealed G2/M phase arrest in TNBC cells. Gene expression analysis showed upregulation of ERBB2, <i>NOTCH1</i>, <i>EGFR</i>, <i>PIK3CA</i>, and <i>PTEN</i> in MDA-MB-231 cells, while 4T1 cells exhibited downregulation of most genes except <i>NOTCH1</i>.</p><p><strong>Conclusion: </strong>This study provides initial evidence for trastuzumab's potential therapeutic effects in TNBC, despite low <i>HER2</i> expression. The observed cytotoxicity, apoptosis induction, and cell cycle modulation in TNBC cells warrant further investigation into trastuzumab's mechanisms of action in <i>HER2</i>-negative contexts and its potential repurposing for TNBC treatment.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241285411"},"PeriodicalIF":1.8,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Histopathology of Abemaciclib-Induced Interstitial Lung Disease: A First Case Report With Transbronchial Lung Cryobiopsy. Abemaciclib诱发间质性肺病的组织病理学:经支气管肺冷冻生物切片检查的首例病例报告
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241301314
Shota Kaburaki, Toru Tanaka, Akari Murata, Koichiro Kamio, Yosuke Tanaka, Yasuhiro Terasaki, Kazuo Kasahara, Masahiro Seike

Abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, is crucial in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic or recurrent breast cancer. However, its association with drug-induced interstitial lung disease (DI-ILD) is concerning. We present an 82-year-old woman with breast cancer receiving abemaciclib, who developed persistent cough and malaise. Initial diagnostics suggested pneumonia, supported by ground-glass opacities and consolidations on chest high-resolution computed tomography. Suspecting DI-ILD, a transbronchial lung cryobiopsy (TBLC) was performed, revealing fibrosing organizing pneumonia and confirming abemaciclib-induced ILD. Discontinuing abemaciclib led to significant symptom improvement, supporting the diagnosis. This case report describes the clinical presentation and diagnostic approach in a patient with suspected abemaciclib-induced ILD, including the use. To our knowledge, this is the first reported case of fibrosing organizing pneumonia as a histopathological pattern in abemaciclib-induced ILD, expanding knowledge of this therapy's pulmonary adverse events. Histopathological features included diffuse lymphocytic infiltration, polypoid intra-alveolar fibrosis, intraluminal granulation tissue plugs with dense hyalinization, hyalinized fibrotic alveolar septa lesions, and obliterative fibrotic processes affecting alveolar ducts. Our case suggests that TBLC might be useful in recognizing DI-ILD by providing detailed lung tissue examination, which can facilitate early diagnosis and guide management. Identifying fibrosing organizing pneumonia indicated a potentially corticosteroid-responsive pathology, suggesting a more favorable prognosis compared with patterns like diffuse alveolar damage. This case highlights the potential for abemaciclib-induced ILD to occur even after prolonged treatment periods, emphasizing the importance of vigilance and consideration of diagnostic intervention for patients on cyclin-dependent kinase 4/6 inhibitors presenting with respiratory symptoms. Timely recognition and appropriate management may mitigate adverse outcomes. Further studies are needed to confirm these findings and to better understand the role of TBLC and histopathological examination in diagnosing and managing abemaciclib-induced ILD.

Abemaciclib是一种细胞周期蛋白依赖性激酶4/6抑制剂,在治疗激素受体阳性、人表皮生长因子受体2阴性的转移性或复发性乳腺癌中起着至关重要的作用。然而,它与药物诱发间质性肺病(DI-ILD)的关系令人担忧。我们为您介绍一位 82 岁的女性乳腺癌患者,她在接受阿巴西利(abemaciclib)治疗后出现持续咳嗽和不适。初步诊断显示为肺炎,胸部高分辨率计算机断层扫描结果显示为磨玻璃不透明和合并症。出于对 DI-ILD 的怀疑,患者接受了经支气管肺冷冻活组织检查(TBLC),结果显示为纤维组织性肺炎,并证实了阿巴西利布诱发的 ILD。停用阿巴西利后症状明显改善,为诊断提供了支持。本病例报告描述了一名疑似阿巴西利诱导的 ILD 患者的临床表现和诊断方法,包括阿巴西利的使用。据我们所知,这是首例将纤维组织化肺炎作为阿贝昔单抗诱导的ILD的组织病理学模式的报道,拓展了对该疗法肺部不良事件的认识。组织病理学特征包括弥漫性淋巴细胞浸润、肺泡内多形性纤维化、致密透明的腔内肉芽组织栓塞、透明化的纤维化肺泡间隔病变以及影响肺泡导管的闭塞性纤维化过程。我们的病例表明,TBLC 可提供详细的肺组织检查,有助于识别 DI-ILD,从而有助于早期诊断和指导治疗。识别纤维组织性肺炎表明该病理可能对皮质类固醇有反应,与弥漫性肺泡损伤等模式相比,预后更佳。本病例强调了阿贝昔单抗诱导的ILD即使在长期治疗后仍有可能发生,并强调了对出现呼吸道症状的细胞周期蛋白依赖性激酶4/6抑制剂患者保持警惕和考虑诊断干预的重要性。及时识别和适当处理可减轻不良后果。还需要进一步的研究来证实这些发现,并更好地了解TBLC和组织病理学检查在诊断和管理阿巴西利诱导的ILD中的作用。
{"title":"The Histopathology of Abemaciclib-Induced Interstitial Lung Disease: A First Case Report With Transbronchial Lung Cryobiopsy.","authors":"Shota Kaburaki, Toru Tanaka, Akari Murata, Koichiro Kamio, Yosuke Tanaka, Yasuhiro Terasaki, Kazuo Kasahara, Masahiro Seike","doi":"10.1177/11782234241301314","DOIUrl":"10.1177/11782234241301314","url":null,"abstract":"<p><p>Abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, is crucial in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic or recurrent breast cancer. However, its association with drug-induced interstitial lung disease (DI-ILD) is concerning. We present an 82-year-old woman with breast cancer receiving abemaciclib, who developed persistent cough and malaise. Initial diagnostics suggested pneumonia, supported by ground-glass opacities and consolidations on chest high-resolution computed tomography. Suspecting DI-ILD, a transbronchial lung cryobiopsy (TBLC) was performed, revealing fibrosing organizing pneumonia and confirming abemaciclib-induced ILD. Discontinuing abemaciclib led to significant symptom improvement, supporting the diagnosis. This case report describes the clinical presentation and diagnostic approach in a patient with suspected abemaciclib-induced ILD, including the use. To our knowledge, this is the first reported case of fibrosing organizing pneumonia as a histopathological pattern in abemaciclib-induced ILD, expanding knowledge of this therapy's pulmonary adverse events. Histopathological features included diffuse lymphocytic infiltration, polypoid intra-alveolar fibrosis, intraluminal granulation tissue plugs with dense hyalinization, hyalinized fibrotic alveolar septa lesions, and obliterative fibrotic processes affecting alveolar ducts. Our case suggests that TBLC might be useful in recognizing DI-ILD by providing detailed lung tissue examination, which can facilitate early diagnosis and guide management. Identifying fibrosing organizing pneumonia indicated a potentially corticosteroid-responsive pathology, suggesting a more favorable prognosis compared with patterns like diffuse alveolar damage. This case highlights the potential for abemaciclib-induced ILD to occur even after prolonged treatment periods, emphasizing the importance of vigilance and consideration of diagnostic intervention for patients on cyclin-dependent kinase 4/6 inhibitors presenting with respiratory symptoms. Timely recognition and appropriate management may mitigate adverse outcomes. Further studies are needed to confirm these findings and to better understand the role of TBLC and histopathological examination in diagnosing and managing abemaciclib-induced ILD.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241301314"},"PeriodicalIF":1.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast Cancer Knowledge and Attitude Toward Breast Cancer Screening Practice Among Catholic Nuns in Lake Zone-Tanzania. 坦桑尼亚湖区天主教修女的乳腺癌知识和对乳腺癌筛查实践的态度。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241301312
Gotfrida Marandu, Kija Malale, Rose Laisser, Joseph Mwanga, Peter Rambau

Background: Breast cancer poses a significant public health challenge in Tanzania. Limited knowledge about breast cancer and negative attitudes toward screening practices contributes to delayed diagnoses and poorer patient outcomes. Catholic nuns, who are often nulliparous, represent a population with an increased risk of developing breast cancer. Despite this risk, they remain an understudied group regarding breast cancer awareness and screening practices.

Objective: This study aimed to assess breast cancer knowledge and attitudes toward screening practices among Catholic nuns residing in Tanzania's Lake Zone.

Study design: The study was a cross-sectional design.

Methods: A total of 385 Catholic nuns participated in the study. To ensure a representative sample, nuns were chosen through simple random sampling, giving each Catholic nun an equal probability of being selected. Data were collected using a self-administered questionnaire and then analyzed using STATA version 18.0. Both descriptive and inferential statistics were used to draw conclusions. In inferential statistics, logistic regression was used to test for associations between categorical variables. The test statistics were considered significant when the P-value was less than .05 at a 95% confidence interval (CI).

Results: This study enrolled 385 catholic nuns. 57.1% (95% CI, 52.0%-62.1%) of all surveyed catholic nuns had inadequate knowledge of breast cancer. Misconceptions also emerged as significant risk factors for inadequate knowledge. Thus, lack of awareness of breast cancer risk factors increased the odds by 5.57 times (adjusted odds ratio [AOR]: 5.57; 95% CI: 2.84-10.92; P < .001). In addition, believing cancer was not inheritable (AOR: 2.65; 95% CI: 1.14-6.15; P = .024), misperceiving oneself as being in a low-risk group (AOR: 1.65; 95% CI: 1.03-2.66; P = .039), and underestimating the vulnerable age group (believing it is not above 40 years) (AOR: 2.60; 95% CI: 1.49-4.51; P = .001) were all significantly associated with higher odds of inadequate knowledge. Regarding the attitude toward breast cancer screening practices, 62.3% (95% CI, 57.3%-67.2%) of the catholic nuns had negative attitudes.

Conclusion: These findings highlight the need for breast health intervention educational programs to improve breast cancer awareness among Catholic nuns. Such programs should address risk factors, symptoms, screening methods, and treatment options, dispelling misconceptions. By empowering nuns with knowledge, they can make informed decisions about their health and take charge of their well-being.

背景:在坦桑尼亚,乳腺癌是一项重大的公共卫生挑战。人们对乳腺癌的了解有限,对乳腺癌筛查的态度消极,这导致了乳腺癌诊断的延迟和患者治疗效果的下降。天主教修女通常都是一夫一妻制,是罹患乳腺癌风险较高的人群。尽管存在这种风险,但她们仍然是乳腺癌认知和筛查实践方面研究不足的群体:本研究旨在评估居住在坦桑尼亚湖区的天主教修女对乳腺癌的认识以及对筛查做法的态度:研究设计:采用横断面设计:共有 385 名天主教修女参加了研究。为确保样本的代表性,修女是通过简单随机抽样选出的,每个天主教修女被选中的概率相等。研究使用自填式问卷收集数据,然后使用 STATA 18.0 版进行分析。在得出结论时使用了描述性和推论性统计方法。在推理统计中,使用逻辑回归法检验分类变量之间的关联。当 P 值小于 0.05 且置信区间(CI)为 95% 时,测试统计结果被认为是有意义的:本研究共招募了 385 名天主教修女。在所有接受调查的天主教修女中,57.1%(95% CI,52.0%-62.1%)的修女对乳腺癌缺乏足够的了解。误解也是导致知识不足的重要风险因素。因此,缺乏对乳腺癌风险因素的认识会使患病几率增加 5.57 倍(调整几率比 [AOR]:5.57;95% CI:2.84-10.92;P P = .024),误认为自己属于低风险群体(AOR:1.65;95% CI:1.03-2.66;P = .039)、低估易患年龄组(认为不超过 40 岁)(AOR:2.60;95% CI:1.49-4.51;P = .001)都与知识不足的几率较高显著相关。关于对乳腺癌筛查做法的态度,62.3%(95% CI,57.3%-67.2%)的天主教修女持消极态度:这些发现突出表明,有必要开展乳腺健康干预教育计划,以提高天主教修女对乳腺癌的认识。此类计划应针对风险因素、症状、筛查方法和治疗方案,消除误解。通过增强修女的知识,她们可以对自己的健康做出明智的决定,并对自己的健康负责。
{"title":"Breast Cancer Knowledge and Attitude Toward Breast Cancer Screening Practice Among Catholic Nuns in Lake Zone-Tanzania.","authors":"Gotfrida Marandu, Kija Malale, Rose Laisser, Joseph Mwanga, Peter Rambau","doi":"10.1177/11782234241301312","DOIUrl":"10.1177/11782234241301312","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer poses a significant public health challenge in Tanzania. Limited knowledge about breast cancer and negative attitudes toward screening practices contributes to delayed diagnoses and poorer patient outcomes. Catholic nuns, who are often nulliparous, represent a population with an increased risk of developing breast cancer. Despite this risk, they remain an understudied group regarding breast cancer awareness and screening practices.</p><p><strong>Objective: </strong>This study aimed to assess breast cancer knowledge and attitudes toward screening practices among Catholic nuns residing in Tanzania's Lake Zone.</p><p><strong>Study design: </strong>The study was a cross-sectional design.</p><p><strong>Methods: </strong>A total of 385 Catholic nuns participated in the study. To ensure a representative sample, nuns were chosen through simple random sampling, giving each Catholic nun an equal probability of being selected. Data were collected using a self-administered questionnaire and then analyzed using STATA version 18.0. Both descriptive and inferential statistics were used to draw conclusions. In inferential statistics, logistic regression was used to test for associations between categorical variables. The test statistics were considered significant when the <i>P</i>-value was less than .05 at a 95% confidence interval (CI).</p><p><strong>Results: </strong>This study enrolled 385 catholic nuns. 57.1% (95% CI, 52.0%-62.1%) of all surveyed catholic nuns had inadequate knowledge of breast cancer. Misconceptions also emerged as significant risk factors for inadequate knowledge. Thus, lack of awareness of breast cancer risk factors increased the odds by 5.57 times (adjusted odds ratio [AOR]: 5.57; 95% CI: 2.84-10.92; <i>P</i> < .001). In addition, believing cancer was not inheritable (AOR: 2.65; 95% CI: 1.14-6.15; <i>P</i> = .024), misperceiving oneself as being in a low-risk group (AOR: 1.65; 95% CI: 1.03-2.66; <i>P</i> = .039), and underestimating the vulnerable age group (believing it is not above 40 years) (AOR: 2.60; 95% CI: 1.49-4.51; <i>P</i> = .001) were all significantly associated with higher odds of inadequate knowledge. Regarding the attitude toward breast cancer screening practices, 62.3% (95% CI, 57.3%-67.2%) of the catholic nuns had negative attitudes.</p><p><strong>Conclusion: </strong>These findings highlight the need for breast health intervention educational programs to improve breast cancer awareness among Catholic nuns. Such programs should address risk factors, symptoms, screening methods, and treatment options, dispelling misconceptions. By empowering nuns with knowledge, they can make informed decisions about their health and take charge of their well-being.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241301312"},"PeriodicalIF":1.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study. 通过循环肿瘤 DNA 分析检测 HER2 阳性早期乳腺癌微小残留病灶并配合新辅助化疗的多中心前瞻性研究:HARMONY 研究。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-27 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241288671
Momoko Tokura, Mark Malalay Ando, Yuki Kojima, Rui Kitadai, Shu Yazaki, Cyrielle Marie N Atutubo, Rubi K Li, Minda Z Perez, Agnes E Gorospe, Manuelito A Madrid, Mel Valerie C Ordinario, Marcelo Severino B Imasa, Kazuki Sudo, Tatsunori Shimoi, Akihiko Suto, Shinji Kohsaka, Ryunosuke Machida, Ryo Sadachi, Masayuki Yoshida, Yasushi Yatabe, Tomomi Hata, Kenichi Nakamura, Kan Yonemori, Sho Shiino

Background: Biomarkers to predict the recurrence risk are required to optimize perioperative treatment. Adjuvant chemotherapy for patients with human epidermal growth factor 2-positive (HER2-positive) early breast cancer is decided by pathological responses of neoadjuvant chemotherapy (NAC). However, whether pathological responses are appropriate biomarkers is unclear. Currently, there are several studies using minimal residual disease (MRD) as a predictor of prognosis in solid tumors. However, there is no standard method for detecting MRD.

Objectives: This study aimed at prospectively evaluating the relationship between MRD detection and recurrence in Asian patients with HER2-positive early breast cancer.

Design: Prospective, observational, single-group, and exploratory. This study will include 60 patients from 2 institutions in Japan and the Philippines. The invasive disease-free survival (IDFS) rates of the MRD-positive and MRD-negative groups are compared in patients with HER2-positive early breast cancer who undergo surgery after receiving NAC.

Methods and analysis: Circulating tumor DNA (ctDNA) levels of patients will be evaluated 6 times: before NAC, after NAC, after surgery, and annually after surgery for 3 years. We will analyze the genetic profile of blood and tissue samples using the Todai OncoPanel (TOP) and the methylation level of DNA. The primary endpoint is IDFS. Secondary endpoints include overall survival (OS) and disease-free survival (DFS). Patient enrollment began in June 2022, and new participants are still being recruited.

Ethics: This study has been approved by the National Cancer Center Hospital Certified Review Board in March 2022 and has been approved by the Research Ethics Board of the participating center.

Discussion: Our findings will contribute to determining whether MRD detection using TOP is useful for predicting the recurrence of HER2-positive early breast cancer. If this is proven, MRD detected by TOP could be used in the future as a biomarker to assist in the de-/escalation of treatment strategies in the next interventional trial, thereby avoiding overtreatment in patients at low risk, and in the addition of intensive treatment modalities for those in patients at high risk.

背景:预测复发风险的生物标志物是优化围手术期治疗所必需的。人类表皮生长因子 2 阳性(HER2 阳性)早期乳腺癌患者的辅助化疗是根据新辅助化疗(NAC)的病理反应决定的。然而,病理反应是否是适当的生物标志物尚不清楚。目前,有几项研究将最小残留病灶(MRD)作为实体瘤预后的预测指标。然而,目前还没有检测MRD的标准方法:本研究旨在前瞻性评估亚洲 HER2 阳性早期乳腺癌患者 MRD 检测与复发之间的关系:设计:前瞻性、观察性、单组和探索性。本研究将包括来自日本和菲律宾两家机构的 60 名患者。比较接受 NAC 后接受手术的 HER2 阳性早期乳腺癌患者中 MRD 阳性组和 MRD 阴性组的侵袭性无病生存率(IDFS):将对患者的循环肿瘤DNA(ctDNA)水平进行6次评估:NAC前、NAC后、手术后以及手术后3年内的每年评估。我们将使用 Todai OncoPanel(TOP)分析血液和组织样本的基因图谱以及 DNA 的甲基化水平。主要终点是 IDFS。次要终点包括总生存期(OS)和无病生存期(DFS)。患者招募始于 2022 年 6 月,目前仍在招募新的参与者:本研究已于2022年3月获得国家癌症中心医院认证审查委员会的批准,并已获得参与中心研究伦理委员会的批准:我们的研究结果将有助于确定使用TOP检测MRD是否有助于预测HER2阳性早期乳腺癌的复发。如果这一点得到证实,那么在下一次干预试验中,TOP检测到的MRD可作为一种生物标志物,协助治疗策略的去级/升级,从而避免低危患者的过度治疗,并为高危患者增加强化治疗模式。
{"title":"Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study.","authors":"Momoko Tokura, Mark Malalay Ando, Yuki Kojima, Rui Kitadai, Shu Yazaki, Cyrielle Marie N Atutubo, Rubi K Li, Minda Z Perez, Agnes E Gorospe, Manuelito A Madrid, Mel Valerie C Ordinario, Marcelo Severino B Imasa, Kazuki Sudo, Tatsunori Shimoi, Akihiko Suto, Shinji Kohsaka, Ryunosuke Machida, Ryo Sadachi, Masayuki Yoshida, Yasushi Yatabe, Tomomi Hata, Kenichi Nakamura, Kan Yonemori, Sho Shiino","doi":"10.1177/11782234241288671","DOIUrl":"10.1177/11782234241288671","url":null,"abstract":"<p><strong>Background: </strong>Biomarkers to predict the recurrence risk are required to optimize perioperative treatment. Adjuvant chemotherapy for patients with human epidermal growth factor 2-positive (HER2-positive) early breast cancer is decided by pathological responses of neoadjuvant chemotherapy (NAC). However, whether pathological responses are appropriate biomarkers is unclear. Currently, there are several studies using minimal residual disease (MRD) as a predictor of prognosis in solid tumors. However, there is no standard method for detecting MRD.</p><p><strong>Objectives: </strong>This study aimed at prospectively evaluating the relationship between MRD detection and recurrence in Asian patients with HER2-positive early breast cancer.</p><p><strong>Design: </strong>Prospective, observational, single-group, and exploratory. This study will include 60 patients from 2 institutions in Japan and the Philippines. The invasive disease-free survival (IDFS) rates of the MRD-positive and MRD-negative groups are compared in patients with HER2-positive early breast cancer who undergo surgery after receiving NAC.</p><p><strong>Methods and analysis: </strong>Circulating tumor DNA (ctDNA) levels of patients will be evaluated 6 times: before NAC, after NAC, after surgery, and annually after surgery for 3 years. We will analyze the genetic profile of blood and tissue samples using the Todai OncoPanel (TOP) and the methylation level of DNA. The primary endpoint is IDFS. Secondary endpoints include overall survival (OS) and disease-free survival (DFS). Patient enrollment began in June 2022, and new participants are still being recruited.</p><p><strong>Ethics: </strong>This study has been approved by the National Cancer Center Hospital Certified Review Board in March 2022 and has been approved by the Research Ethics Board of the participating center.</p><p><strong>Discussion: </strong>Our findings will contribute to determining whether MRD detection using TOP is useful for predicting the recurrence of HER2-positive early breast cancer. If this is proven, MRD detected by TOP could be used in the future as a biomarker to assist in the de-/escalation of treatment strategies in the next interventional trial, thereby avoiding overtreatment in patients at low risk, and in the addition of intensive treatment modalities for those in patients at high risk.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241288671"},"PeriodicalIF":1.8,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ENO1 as a Biomarker of Breast Cancer Progression and Metastasis: A Bioinformatic Approach Using Available Databases. ENO1作为乳腺癌进展和转移的生物标记物:利用现有数据库的生物信息学方法。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-19 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241285648
Athina Giannoudis, Alistair Heath, Vijay Sharma

Background: Metabolic reprogramming is one of the hallmarks of cancer, and in breast cancer (BC), several metabolic enzymes are overexpressed and overactivated. One of these, Enolase 1 (ENO1), catalyses glycolysis and is involved in the regulation of multiple signalling pathways.

Objectives: This study aimed to evaluate in silico the prognostic and predictive effects of ENO1 expression in BC.

Design: This is a bioinformatic in silico analysis.

Methods: Using available online platforms (Kaplan-Meier [KM] plotter, receiver operating characteristic curve [ROC] plotter, cBioPortal, Genotype-2-Outcome [G-2-O], MethSurv, and Tumour-Immune System Interaction Database [TISIDB]), we performed a bioinformatic in silico analysis to establish the prognostic and predictive effects related to ENO1 expression in BC. A network analysis was performed using the Oncomine platform, and signalling, epigenetic, and immune regulation pathways were explored.

Results: ENO1 was overexpressed in all the analysed Oncomine, epigenetic, and immune pathways in triple-negative, but not in hormone receptor-positive BCs. In human epidermal growth factor receptor 2 (HER2)-positive BCs, ENO1 expression showed a mixed profile. Analysis on disease progression and histological types showed ENO1 overexpression in ductal in situ and invasive carcinoma, in high-grade tumours followed by advanced or metastasis and was linked to worse survival. High ENO1 expression was also associated with relapse-free, distant metastasis-free and overall survival, irrespectively of treatment and was mainly related to basal subtype.

Conclusion: ENO1 overexpression recruits a range of signalling pathways during disease progression conferring a worse prognosis and can be potentially used as a biomarker of disease progression and therapeutic target, particularly in triple-negative and in ductal invasive carcinoma.

背景:代谢重编程是癌症的标志之一,在乳腺癌(BC)中,有几种代谢酶过度表达和过度激活。其中的烯醇化酶1(ENO1)催化糖酵解,并参与多种信号通路的调控:本研究旨在对 BC 中 ENO1 表达的预后和预测作用进行硅学评估:设计:这是一项生物信息学硅学分析:利用现有的在线平台(Kaplan-Meier [KM] plotter、接收者操作特征曲线[ROC] plotter、cBioPortal、Genotype-2-Outcome [G-2-O]、MethSurv和肿瘤-免疫系统相互作用数据库[TISIDB]),我们进行了生物信息学硅学分析,以确定与ENO1在BC中的表达有关的预后和预测作用。我们使用 Oncomine 平台进行了网络分析,探索了信号、表观遗传和免疫调节通路:结果:在所有分析的Oncomine、表观遗传和免疫通路中,ENO1在三阴性而非激素受体阳性的BC中都存在过表达。在人表皮生长因子受体2(HER2)阳性的碱性细胞癌中,ENO1的表达呈现混合型。对疾病进展和组织学类型的分析表明,ENO1在导管原位癌和浸润癌、高级别肿瘤以及晚期或转移癌中过度表达,并与生存率降低有关。ENO1的高表达还与无复发、无远处转移和总生存有关,与治疗无关,主要与基底亚型有关:结论:ENO1的过度表达在疾病进展过程中招募了一系列信号通路,导致预后恶化,有可能被用作疾病进展的生物标记物和治疗靶点,尤其是在三阴性和导管浸润癌中。
{"title":"ENO1 as a Biomarker of Breast Cancer Progression and Metastasis: A Bioinformatic Approach Using Available Databases.","authors":"Athina Giannoudis, Alistair Heath, Vijay Sharma","doi":"10.1177/11782234241285648","DOIUrl":"10.1177/11782234241285648","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming is one of the hallmarks of cancer, and in breast cancer (BC), several metabolic enzymes are overexpressed and overactivated. One of these, Enolase 1 (ENO1), catalyses glycolysis and is involved in the regulation of multiple signalling pathways.</p><p><strong>Objectives: </strong>This study aimed to evaluate in silico the prognostic and predictive effects of ENO1 expression in BC.</p><p><strong>Design: </strong>This is a bioinformatic in silico analysis.</p><p><strong>Methods: </strong>Using available online platforms (Kaplan-Meier [KM] plotter, receiver operating characteristic curve [ROC] plotter, cBioPortal, Genotype-2-Outcome [G-2-O], MethSurv, and Tumour-Immune System Interaction Database [TISIDB]), we performed a bioinformatic in silico analysis to establish the prognostic and predictive effects related to ENO1 expression in BC. A network analysis was performed using the Oncomine platform, and signalling, epigenetic, and immune regulation pathways were explored.</p><p><strong>Results: </strong>ENO1 was overexpressed in all the analysed Oncomine, epigenetic, and immune pathways in triple-negative, but not in hormone receptor-positive BCs. In human epidermal growth factor receptor 2 (HER2)-positive BCs, ENO1 expression showed a mixed profile. Analysis on disease progression and histological types showed ENO1 overexpression in ductal in situ and invasive carcinoma, in high-grade tumours followed by advanced or metastasis and was linked to worse survival. High ENO1 expression was also associated with relapse-free, distant metastasis-free and overall survival, irrespectively of treatment and was mainly related to basal subtype.</p><p><strong>Conclusion: </strong>ENO1 overexpression recruits a range of signalling pathways during disease progression conferring a worse prognosis and can be potentially used as a biomarker of disease progression and therapeutic target, particularly in triple-negative and in ductal invasive carcinoma.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241285648"},"PeriodicalIF":1.8,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of Life in Female Breast Cancer Patients and Survivors in a South African Municipality. 南非某市女性乳腺癌患者和幸存者的生活质量。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241282519
Rebecca Wilkinson, Lynn Smith

Background: Breast cancer diagnosis and treatment processes affect patients physically and mentally, and have an impact on their quality of life, even years after receiving treatment.

Objectives: The objective of this study was to determine the quality of life in female breast cancer patients and survivors in a South African context. The municipality within which participants were recruited for this study was Ekurhuleni, based in the Gauteng province, South Africa.

Design: This study followed a cross-sectional research design. Quantitative data was collected.

Methods: The Quality-of-Life Patient/Cancer Survivor Version (2012) was used to determine participants' quality of life in 4 subscales, namely, physical, psychological, social, and spiritual. The questionnaire was accessible to participants via the online Google Forms platform as well as in hard-copy format at local medical facilities. The Statistical Package for Social Sciences (SPSS) was used to compute statistics, and the level of significance was set at 95% (P < .05).

Results: One hundred female breast cancer patients and survivors from the region of Ekurhuleni, South Africa, took part in this study. The findings demonstrate that the quality-of-life subscale with the highest score was spiritual well-being (6.66 ± 2.07) and the lowest was psychological well-being (4.91 ± 1.93). No significant difference was found between quality of life and type of facility attended. Significant differences were found in quality-of-life ratings between breast cancer patient and breast cancer survivor populations.

Conclusion: Breast cancer can result in a compromised quality of life, and with the increased prevalence and survival rate of breast cancer patients, both the short- and long-term effects of the condition and its treatments are heightened.

背景:乳腺癌的诊断和治疗过程会影响患者的身心健康,甚至在接受治疗多年后仍会影响其生活质量:本研究旨在确定南非女性乳腺癌患者和幸存者的生活质量。本研究的参与者被招募到南非豪登省的埃库尔胡莱尼市:本研究采用横断面研究设计,收集定量数据。收集定量数据:采用生活质量患者/癌症幸存者版本(2012 年)来确定参与者在身体、心理、社交和精神四个分量表中的生活质量。参与者可通过在线谷歌表格平台获取问卷,也可在当地医疗机构获取硬拷贝形式的问卷。统计结果采用社会科学统计软件包(SPSS)进行计算,显著性水平设定为 95%(P 结果):来自南非埃库尔胡莱尼地区的 100 名女性乳腺癌患者和幸存者参加了此次研究。研究结果表明,生活质量分量表中得分最高的是精神幸福感(6.66 ± 2.07),最低的是心理幸福感(4.91 ± 1.93)。生活质量与就医机构类型之间没有发现明显差异。乳腺癌患者和乳腺癌幸存者的生活质量评分存在明显差异:结论:乳腺癌可导致生活质量下降,随着乳腺癌发病率和存活率的增加,乳腺癌及其治疗的短期和长期影响也随之增加。
{"title":"Quality of Life in Female Breast Cancer Patients and Survivors in a South African Municipality.","authors":"Rebecca Wilkinson, Lynn Smith","doi":"10.1177/11782234241282519","DOIUrl":"10.1177/11782234241282519","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer diagnosis and treatment processes affect patients physically and mentally, and have an impact on their quality of life, even years after receiving treatment.</p><p><strong>Objectives: </strong>The objective of this study was to determine the quality of life in female breast cancer patients and survivors in a South African context. The municipality within which participants were recruited for this study was Ekurhuleni, based in the Gauteng province, South Africa.</p><p><strong>Design: </strong>This study followed a cross-sectional research design. Quantitative data was collected.</p><p><strong>Methods: </strong>The Quality-of-Life Patient/Cancer Survivor Version (2012) was used to determine participants' quality of life in 4 subscales, namely, physical, psychological, social, and spiritual. The questionnaire was accessible to participants via the online Google Forms platform as well as in hard-copy format at local medical facilities. The Statistical Package for Social Sciences (SPSS) was used to compute statistics, and the level of significance was set at 95% (<i>P</i> < .05).</p><p><strong>Results: </strong>One hundred female breast cancer patients and survivors from the region of Ekurhuleni, South Africa, took part in this study. The findings demonstrate that the quality-of-life subscale with the highest score was spiritual well-being (6.66 ± 2.07) and the lowest was psychological well-being (4.91 ± 1.93). No significant difference was found between quality of life and type of facility attended. Significant differences were found in quality-of-life ratings between breast cancer patient and breast cancer survivor populations.</p><p><strong>Conclusion: </strong>Breast cancer can result in a compromised quality of life, and with the increased prevalence and survival rate of breast cancer patients, both the short- and long-term effects of the condition and its treatments are heightened.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241282519"},"PeriodicalIF":1.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast Cancer : Basic and Clinical Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1